Ischemic stroke is amongst the leading causes of death and disabilities. The available treatments are suitable for only a fraction of patients and thus novel therapies are urgently needed. Blockage of one of the cerebral arteries leads to massive and persisting inflammatory reaction contributing to the nearby neuronal damage. Targeting the detrimental pathways of neuroinflammation has been suggested to be beneficial in conditions of ischemic stroke. Nuclear receptor 4A-family (NR4A) member Nurr1 has been shown to be a potent modulator of harmful inflammatory reactions, yet the role of Nurr1 in cerebral stroke remains unknown. Here we show for the first time that an agonist for the dimeric transcription factor Nurr1/retinoid X receptor (RXR), HX600, reduces microglia expressed proinflammatory mediators and prevents inflammation induced neuronal death in in vitro coculture model of neurons and microglia. Importantly, HX600 was protective in a mouse model of permanent middle cerebral artery occlusion and alleviated the stroke induced motor deficits. Along with the anti-inflammatory capacity of HX600 in vitro, treatment of ischemic mice with HX600 reduced ischemia induced Iba-1, p38 and TREM2 immunoreactivities, protected endogenous microglia from ischemia induced death and prevented leukocyte infiltration. These anti-inflammatory functions were associated with reduced levels of brain lysophosphatidylcholines (lysoPCs) and acylcarnitines, metabolites related to proinflammatory events. These data demonstrate that HX600 driven Nurr1 activation is beneficial in ischemic stroke and propose that targeting Nurr1 is a novel candidate for conditions involving neuroinflammatory component.
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Introduction
Ischemic stroke is a severe cerebrovascular disease caused by blockage of blood flow into the brain. It is one of the leading causes of death (GBD, 2015) influencing mainly the elderly, yet a growing portion of individuals affected are still at working age (Kissela et al., 2012; Béjot et al., 2014) . If not causing imminent death, stroke is likely to lead to permanent disabilities markedly diminishing the quality of life of the affected individuals and their families. Thus, stroke is causing an enormous burden for the society and economy (Stroke Facts, 2017) . While mechanical thrombectomy is highly beneficial in large vessel occlusions in the anterior circulation (Evans et al., 2017) , recombinant tissue plasminogen activator (r-tPA) still remains the only clinically approved pharmacological treatment for cerebral stroke, yet it is suitable for only https://doi.org/10.1016/j.bbi.2018.07.021 Received 27 April 2018; Received in revised form 14 July 2018; Accepted 25 July 2018
